Hanmi Pharm (KRX:128940) posted first-quarter net income attributable to shareholders of the parent company of 42.6 billion won, down 22.5% from 55 billion won a year earlier, the pharmaceutical company said in a Tuesday regulatory filing with Korea Exchange.

The company's sales fell 3.2% year over year to 390.9 billion won from 403.7 billion won.

Shares of Hanmi Pharm jumped nearly 9% at market close on Wednesday, April 30.